BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brown HC, Doering CB, Herzog RW, Ling C, Markusic DM, Spencer HT, Srivastava A, Srivastava A. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B. Hum Gene Ther 2020;31:1114-23. [PMID: 32657150 DOI: 10.1089/hum.2020.099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Srivastava A. AAV Vectors: Are They Safe? Hum Gene Ther 2020;31:697-9. [PMID: 32611206 DOI: 10.1089/hum.2020.187] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
2 Reiss UM, Mahlangu J, Ohmori T, Ozelo MC, Srivastava A, Zhang L. Haemophilia gene therapy-Update on new country initiatives. Haemophilia 2022;28 Suppl 4:61-7. [PMID: 35521726 DOI: 10.1111/hae.14512] [Reference Citation Analysis]
3 Kumar SRP, Xie J, Hu S, Ko J, Huang Q, Brown HC, Srivastava A, Markusic DM, Doering CB, Spencer HT, Srivastava A, Gao G, Herzog RW. Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette. Mol Ther Methods Clin Dev 2021;23:98-107. [PMID: 34631930 DOI: 10.1016/j.omtm.2021.08.001] [Reference Citation Analysis]
4 Cao W, Dong B, Horling F, Firrman JA, Lengler J, Klugmann M, de la Rosa M, Wu W, Wang Q, Wei H, Moore AR, Roberts SA, Booth CJ, Hoellriegl W, Li D, Konkle B, Miao C, Reipert BM, Scheiflinger F, Rottensteiner H, Xiao W. Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency. Mol Ther Methods Clin Dev 2020;19:486-95. [PMID: 33313336 DOI: 10.1016/j.omtm.2020.10.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Knight KA, Coyle CW, Radford CE, Parker ET, Fedanov A, Shields JM, Szlam F, Purchel A, Chen M, Denning G, Sniecinski RM, Lollar P, Spencer HT, Gaucher EA, Doering CB. Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction. Blood Adv 2021;5:3333-43. [PMID: 34477814 DOI: 10.1182/bloodadvances.2021004742] [Reference Citation Analysis]
6 Ito M, Takino N, Nomura T, Kan A, Muramatsu SI. Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies. Sci Rep 2021;11:9322. [PMID: 33927271 DOI: 10.1038/s41598-021-88614-9] [Reference Citation Analysis]
7 Daniel HD, Kumar S, Kannangai R, Lakshmi KM, Agbandje-Mckenna M, Coleman K, Srivastava A, Srivastava A, Abraham AM. Prevalence of Adeno-Associated Virus 3 Capsid Binding and Neutralizing Antibodies in Healthy and Hemophilia B Individuals from India. Hum Gene Ther 2021;32:451-7. [PMID: 33207962 DOI: 10.1089/hum.2020.258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Raj R, Aboobacker FN, Yadav SP, Uppuluri R, Bhat S, Choudhry D, Dua V, Kharya G, Rastogi N, Sachdev M, Khandelwal V, Swaminathan V, Bakane A, Ramakrishnan B, George B. Multicenter Outcome of Hematopoietic Stem Cell Transplantation for Primary Immune Deficiency Disorders in India. Front Immunol 2020;11:606930. [PMID: 33488609 DOI: 10.3389/fimmu.2020.606930] [Reference Citation Analysis]
9 Ohira M, Kikuchi E, Mizuta S, Yoshida N, Onodera M, Nakanishi M, Okuyama T, Mashima R. Production of therapeutic iduronate-2-sulfatase enzyme with a novel single-stranded RNA virus vector. Genes Cells 2021;26:891-904. [PMID: 34480399 DOI: 10.1111/gtc.12894] [Reference Citation Analysis]